Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of "Buy" from Analysts

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) have received an average rating of "Buy" from the five analysts that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $3.50.

A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Lucid Diagnostics from a "hold" rating to a "sell" rating in a research note on Thursday. Ascendiant Capital Markets raised their price target on Lucid Diagnostics from $7.00 to $7.50 and gave the stock a "buy" rating in a research report on Monday, April 21st. BTIG Research set a $2.00 price objective on Lucid Diagnostics in a report on Tuesday, March 25th. Needham & Company LLC restated a "buy" rating and set a $3.00 target price on shares of Lucid Diagnostics in a report on Wednesday, May 14th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $2.00 price objective on shares of Lucid Diagnostics in a report on Thursday, May 15th.

Institutional Trading of Lucid Diagnostics

A number of large investors have recently bought and sold shares of the business. LPL Financial LLC boosted its holdings in shares of Lucid Diagnostics by 29.1% in the fourth quarter. LPL Financial LLC now owns 53,391 shares of the company's stock valued at $44,000 after buying an additional 12,035 shares during the period. Berkshire Asset Management LLC PA acquired a new position in Lucid Diagnostics in the 1st quarter worth $30,000. Goldman Sachs Group Inc. increased its holdings in Lucid Diagnostics by 35.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company's stock worth $129,000 after purchasing an additional 22,727 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Lucid Diagnostics in the first quarter valued at about $37,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Lucid Diagnostics during the first quarter worth about $39,000. 74.01% of the stock is owned by institutional investors.

Lucid Diagnostics Price Performance

Shares of NASDAQ LUCD traded down $0.02 during mid-day trading on Thursday, hitting $1.31. The company's stock had a trading volume of 209,809 shares, compared to its average volume of 506,915. Lucid Diagnostics has a one year low of $0.68 and a one year high of $1.80. The company's fifty day simple moving average is $1.35 and its 200-day simple moving average is $1.14. The stock has a market cap of $141.73 million, a price-to-earnings ratio of -1.15 and a beta of 1.28.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.